A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies

References

• Dedong C, Huilin X, Anbing H, Ximing X, Wei G. The effect of ShenQi FuZheng injection in combination with chemotherapy versus chemotherapy alone on the improvement of efficacy and immune function in patients with advanced non-small cell lung cancer: A meta-analysis. PloS One. 2016;11:e0152270. doi:10.1371/journal.pone.0152270.
   PubMed Web of Science ®Google Scholar
• Shroff GS, De Groot PM, Papadimitrakopoulou VA, Truong MT, Carter BW. Targeted therapy and immunotherapy in the treatment of non-small cell lung cancer. Radiol Clin North Am. 2018;56:485–495. doi:10.1016/j.rcl.2018.01.012.
   PubMed Web of Science ®Google Scholar
• Remon J, Vilarino N, Reguart N. Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): approaches on special subgroups and unresolved burning questions. Cancer Treat Rev. 2018;64:21–29. doi:10.1016/j.ctrv.2018.02.002.
   PubMed Web of Science ®Google Scholar
• Ernani V, Ganti AK. Immunotherapy in treatment naive advanced non-small cell lung cancer. J Thorac Dis. 2018;10:SS412–SS421. doi:10.21037/jtd.
   Web of Science ®Google Scholar
• Bilen MA, Dutcher GMA, Liu Y, Ravindranathan D, Kissick HT, Carthon BC, Kucuk O, Harris WB, Master VA. Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with Nivolumab. Clin Genitourin Cancer. 2018;16:e563–e575. doi:10.1016/j.clgc.2017.12.015.
   PubMed Web of Science ®Google Scholar
• Nomura S, Yokoi T, Kurata T. Platelet-related indices in patients with lung cancer with nivolumab. Platelets. 2018;29:207–208. doi:10.1080/09537104.2017.1356454.
   PubMed Web of Science ®Google Scholar
• Akamine T, Takada K, Toyokawa G, Kinoshita F, Matsubara T, Kozuma Y, Haratake N, Takamori S, Hirai F, Tagawa T, et al. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. Surg Oncol. 2018;27:88–94. doi:10.1016/j.suronc.2018.01.002.
   PubMed Web of Science ®Google Scholar
• Ren M, Dai B, Kong YY, Lv JJ, Cai X. PD-L1 expression in tumor infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients. Histopathology. 2018. doi:10.1111/his.13527.
   Web of Science ®Google Scholar
• Ren L, Matsuda T, Deng B, Kiyotani K, Kato T, Park JH, Seiwert TY, Vokes EE, Agrawal N, Nakamura Y. Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of in vitro expanded populations in head and neck cancer. Oncotarget. 2018;9:3805–3814. doi:10.18632/oncotarget.23454.
   PubMedGoogle Scholar
• Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, et al. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018;6:5. doi:10.1186/s40425-018-0315-0.
   PubMed Web of Science ®Google Scholar
• Tang Y, Li G, Wu S, Tang L, Zhang N, Liu J, Zhang S, Yao L. Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: prognostic significance and association with inflammatory biomarkers. Oncol Lett. 2018;15:4988–4996. doi:10.3892/ol.2018.7984.
   PubMed Web of Science ®Google Scholar
• Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Fujimura T, Yamamoto Y, Hata H, Tanaka R, Yamaguchi K, Nonomura Y, et al. Baseline neutrophil to lymphocyte ratio combined with serum LDH level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population. Br J Dermatol. 2018;179:213–215. doi:10.1111/bjd.2018.179.issue-1.
   PubMed Web of Science ®Google Scholar
• Yu Y, Qian L, Cui J. Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients. Mol Clin Oncol. 2017;7:498–506. doi:10.3892/mco.2017.1342.
   PubMed Web of Science ®Google Scholar
• Gu XB, Tian T, Tian XJ, Zhang XJ. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep. 2015;5:12493. doi:10.1038/srep12493.
   PubMed Web of Science ®Google Scholar
• Peng B, Wang YH, Liu YM, Ma LX. Prognostic significance of the neutrophil to lymphocyte ratio in patients with non-small cell lung cancer: a systemic review and meta-analysis. Int J Clin Exp Med. 2015;8:3098–3106.
   PubMed Web of Science ®Google Scholar
• Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, Kim D-W, Heo DS, Lee JS. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother. 2018;67:459–470. doi:10.1007/s00262-017-2092-x.
   PubMed Web of Science ®Google Scholar
• Nakaya A, Kurata T, Yoshioka H, Takeyasu Y, Niki M, Kibata K, Satsutani N, Ogata M, Miyara T, Nomura S. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. Int J Clin Oncol. 201823:634–640.
   PubMed Web of Science ®Google Scholar
• Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, Tamura D, Tachihara M, Kobayashi K, Nishimura Y, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PloS One. 2018;13:e0193018. doi:10.1371/journal.pone.0193018.
   PubMed Web of Science ®Google Scholar
• Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, Warsch J, Elias R, Chae YK, Kim DW, et al. Developing a predictive model for clinical outcomes of advanced non-small cell lung cancer patients treated with Nivolumab. Clin Lung Cancer. 2018;19:280–288.e4. doi:10.1016/j.cllc.2017.12.007.
   PubMed Web of Science ®Google Scholar
• Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: A review and meta-analysis. Onco Targets Ther. 2018;11:955–965. doi:10.2147/OTT.S153290.
   PubMed Web of Science ®Google Scholar
• Jiang T, Qiao M, Zhao C, Li X, Gao G, Su C, Ren S, Zhou C. Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis. Cancer Immunol Immunother. 2018;67:713–727. doi:10.1007/s00262-018-2126-z.
   PubMed Web of Science ®Google Scholar
• Bartlett E, Ferraro RA, Stacruz JM, Postow MA, Coit D, Ariyan CE. Neutrophil to lymphocyte ratio (NLR) is associated with survival but varies with disease burden in melanoma patients treated with PD-1 inhibitor monotherapy. Ann Surg Oncol. 2018;25:S41.
   Web of Science ®Google Scholar
• Cao DD, Xu HL, Xu XM, Ge W. The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis. Oncotarget. 2017;8:53631–53641. doi:10.18632/oncotarget.19022.
   PubMedGoogle Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–2834.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1. 0. The Cochrane Collaboration. Confidence Intervals, 2011.
   Google Scholar
• Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, Nakahama K, Taniguchi Y, Isa S-I, Inoue T, et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non–small cell lung cancer. Cancer Med. 2018;7:13–20. doi:10.1002/cam4.1234.
   PubMed Web of Science ®Google Scholar
• Russo A, Scimone A, Picciotto M, Toscano G, Raiti F, Sava S, Battaglia A, Adamo V. Association between baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR), and platelet-to-lymphocyte ratio (PLR) and response to nivolumab (Nivo) in non-small cell lung cancer (NSCLC): A preliminary analysis add to collection. J Clin Oncol. 2017:15:e14617. doi:10.1200/JCO.2017.35.
   Google Scholar
• Rogado J, Fenor De La Maza MD, Pacheco-Barcia V, Serra JM, Toquero P, Vera B, Ballesteros A, Mondéjar R, Donnay O, Obispo B, et al. Are inflammatory markers predictive of nivolumab efficacy in advanced non-small-cell lung cancer (NSCLC)? J Thorac Oncol. 2017;12:SS2108–SS2109. doi:10.1016/j.jtho.2017.09.1205.
   Web of Science ®Google Scholar
• Preeshagul IR, Sullivan KM, Paul D, Seetharamu N. The utilization of pretreatment neutrophil to lymphocyte ratio as a predictive marker for response to nivolumab therapy in non small cell lung cancer. J Clin Oncol. 2017;35:e20634. doi:10.1200/JCO.2017.35.
   Web of Science ®Google Scholar
• Patil PD, Khunger M, Rakshit S, Stevenson J, Pennell NA, Elson P, Velcheti V. Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab. J Clin Oncol. 2017;15:11547. doi:10.1200/JCO.2017.35.
   Google Scholar
• Gervais C, Boudou-Rouquette P, Jouinot A, Huillard O, Alexandre J, Arrondeau J, Giraud F, Chapron J, Alifano M, Revel MP, et al. Predictive and prognostic value of systemic inflammatory response biomarkers in patients receiving nivolumab for metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2017;15:3055. doi:10.1200/JCO.2017.35.
   Google Scholar
• Galetta D, Logroscino AF, Misino A, Montagna ES, Petrillo P, Ricci D, Catino A. P3.02c-085 neutrophil/lymphocyte ratio in advanced non-small cell lung cancer: correlation with prognosis and response to Anti-PD1 therapy. J Thorac Oncol. 2017;12:SS1329–SS1330. doi:10.1016/j.jtho.2016.11.1881.
   Web of Science ®Google Scholar
• Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181. doi:10.1016/j.lungcan.2017.07.024.
   PubMed Web of Science ®Google Scholar
• Bennati C, D’Arcangelo M, Minuti G, Vecchiarelli S, Landi L, Mazza V, Gili A, Puccetti M, Cappuzzo F. Programmed cell death ligand 1 and neutrophil to lymphocyte ratio to predict response to nivolumab in non-small cell lung cancer. J Thorac Oncol. 2017;12:SS2390–SS2391. doi:10.1016/j.jtho.2017.09.1939.
   Web of Science ®Google Scholar
• Bagley S, Kothari S, Aggarwal C, Bauml J, Alley E, Evans T, Kosteva J, Ciunci C, Thompson J, Stonehouse-Lee S, et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) predicts outcomes with nivolumab in non-small cell lung cancer (NSCLC). J Thorac Oncol. 2017;12:S1318. doi:10.1016/j.jtho.2016.09.002.
   Web of Science ®Google Scholar
• Soyano AE, Dholaria BR, Marin-Acevedo JA, Diehl NN, Hodge D, Lou Y. Baseline peripheral blood biomarkers associated with clinical outcome of advanced lung cancer in patients treated with anti-PD-1 antibody. J Clin Oncol. 2017;35:e20599–e.
   Web of Science ®Google Scholar
• Bennati C, Mazza V, D’Arcangelo M, Minuti G, Vecchiarelli S, Attilia L, Gili A, Montanari M, Landi L, Cappuzzo F, Integrating programmed cell death ligand 1 (PD-L1) and neutrophil to lymphocyte ratio (NLR) as predictive panel of response to nivolumab in non-small cell lung cancer (NSCLC). Ann Oncol. 2017;28:vi56. doi:10.1093/annonc/mdx075.
   Web of Science ®Google Scholar
• Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 2018;33:581–598. doi:10.1016/j.ccell.2018.03.005.
   PubMed Web of Science ®Google Scholar
• Canova S, Bidoli P, Lissoni P, Abbate MI, Capici S, Casiraghi S, Cortinovis D. Predictive role of absolute lymphocyte count (ALC) and neutrophil/lymphocyte ratio (NLR) in patients with metastatic non small cell lung cancer (NSCLC) treated with nivolumab: results of a retrospective monocentric study. Ann Oncol. 2016;27. doi:10.1093/annonc/mdw141.
   Web of Science ®Google Scholar